Covered recipient · General Payments record
JAMIE MICHELLE DRAKE
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant
General Payments · PY2021–2024
$975.18
- Reported across 51 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $680.79 | 33 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $251.55 | 12 |
| Astellas Pharma US Inc | $98.79 | 5 |
| GlaxoSmithKline, LLC. | $68.50 | 3 |
| PFIZER INC. | $62.39 | 4 |
| Corcept Therapeutics | $52.47 | 2 |
| Acerta Pharma LLC | $36.96 | 2 |
| Exact Sciences Corporation | $26.92 | 1 |
| Amgen Inc. | $25.63 | 1 |
| Axonics Modulation Technologies, Inc. | $23.37 | 1 |
| Merck Sharp & Dohme Corporation | $19.99 | 1 |
| Novo Nordisk AS | $14.22 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (33)
Sorted by paying entity, then date · as published by CMS
Program year 2024 202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $27.76 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107041296 | CMS |
| ABBVIE INC. | $4.40 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107041298 | CMS |
| ABBVIE INC. | $23.45 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107041300 | CMS |
| ABBVIE INC. | $25.28 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107041302 | CMS |
| ABBVIE INC. | $22.46 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107041304 | CMS |
| ABBVIE INC. | $13.12 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107041306 | CMS |
| ABBVIE INC. | $21.79 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107041308 | CMS |
| ABBVIE INC. | $29.24 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107041310 | CMS |
| ABBVIE INC. | $15.43 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107041312 | CMS |
| ABBVIE INC. | $28.07 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107041314 | CMS |
| ABBVIE INC. | $28.07 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107041316 | CMS |
| ABBVIE INC. | $12.48 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107041318 | CMS |
| Amgen Inc. | $25.63 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115585579 | CMS |
| Astellas Pharma US Inc | $20.46 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139476174 | CMS |
| Astellas Pharma US Inc | $20.65 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139477802 | CMS |
| Astellas Pharma US Inc | $18.06 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139502592 | CMS |
| Astellas Pharma US Inc | $22.16 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139528444 | CMS |
| Astellas Pharma US Inc | $17.46 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139537218 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.84 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104208433 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.12 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105339435 | CMS |
| Axonics, Inc. | $23.37 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142396005 | CMS |
| Corcept Therapeutics | $13.69 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117748249 | CMS |
| Corcept Therapeutics | $38.78 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117748319 | CMS |
| Exact Sciences Corporation | $26.92 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114532703 | CMS |
| GlaxoSmithKline, LLC. | $17.32 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116059583 | CMS |
| GlaxoSmithKline, LLC. | $27.01 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116261237 | CMS |
| GlaxoSmithKline, LLC. | $24.17 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116238121 | CMS |
| Merck Sharp & Dohme LLC | $19.99 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141660539 | CMS |
| Novo Nordisk Inc | $14.22 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100442289 | CMS |
| PFIZER INC. | $16.31 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131014014 | CMS |
| PFIZER INC. | $14.79 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131251708 | CMS |
| PFIZER INC. | $17.42 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131777990 | CMS |
| PFIZER INC. | $13.87 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131878258 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.